YOUR BUSINESS AUTHORITY
Springfield, MO
Novartis AG announced it would purchase Endocyte Inc. for $2.1 billion.
The acquisition would give the Swiss pharmaceutical company access to Endocyte's so-called radiopharmaceuticals, which carry radioactive substances to kill tumor cells.
Endocyte is currently developing a new treatment for prostate cancer.
Read more from The Wall Street Journal.
Organizers hope to bolster client traffic to center city businesses.